Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
EBOS Group Limited ( (AU:EBO) ) has provided an update.
EBOS Group Limited has reported a solid performance for the first half of the 2025 financial year, showcasing the strength of its diversified business model. Despite a loss of a significant contract, the company managed to grow its underlying EBITDA by 7.1% and revenue by 9.5%, driven by organic growth and strategic investments. The healthcare segment, which includes community pharmacy and medical technology, saw robust growth, particularly in Australia and Southeast Asia. The animal care segment also performed well, with the branded business leading the way. EBOS continues to focus on sustainable practices and has made significant steps towards renewable energy. The company remains on track to meet its full-year guidance, signaling positive outcomes for stakeholders.
More about EBOS Group Limited
EBOS Group Limited operates in the healthcare and animal care industries, providing a diverse range of products and services including pharmaceuticals, medical technology, and animal care products. The company focuses on strategic acquisitions and expanding its market presence in regions such as Southeast Asia.
YTD Price Performance: 11.44%
Average Trading Volume: 30,142
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$7.28B
For a thorough assessment of EBO stock, go to TipRanks’ Stock Analysis page.
